WillItSurvive
Medical technology and health companies · United States

Myriad Genetics

myriad.com ↗

Lab-based hereditary and cancer genetic testing company using proprietary variant data and counselors.

Losing its protection
Assessed 22 July 2026 · Evidence as of 22 July 2026
The structural protection is eroding.
On the recordSince 22 July 2026 · Checkable from early August 2026 · Every call on the record Checkpoint: Q2 2026 earnings report, testing whether guided second-half reacceleration shows up
The call

Myriad has real data and regulatory protection against AI disruption, but Labcorp, Tempus, and Roche are pulling share in growth segments while leadership and margins remain unsettled.

Myriad runs a lab that reads genes and advises doctors on disease risk and treatment, using 30 years of genetic data and a network of genetic counselors that competitors cannot quickly copy. However, larger companies like Labcorp, Roche, and Natera are taking customers in the faster-growing segments, and Myriad's own growth has slowed to barely 2% per year after years of faster expansion. The company is also thin on profit and losing money overall, and just replaced all three of its top leaders in the past year. What happens next depends heavily on whether insurance companies decide to cover Myriad's new blood test for cancer detection in the second half of 2026 - that decision alone could either revive growth or confirm that Myriad is slipping away.

Why
01
AI pressure: None apparent. Myriad uses AI as an add-on (Prolaris+AI, PATHOMIQ) for scoring, not as a replacement; no AI lab is running its own tests or contracts. Could AI do the core job? Unlikely.
02
Bigger players: Labcorp (absorbed Invitae's hereditary testing operations in 2024). Labcorp now cross-sells Invitae's former hereditary book to shared ordering physicians, pulling volume Myriad used to own outright. Could a giant copy it? Probably.
03
What protects it. A 30-plus year variant database, CLIA lab accreditation, payer contracts, and a genetic counselor network that AI tools cannot replicate or bypass.
What would change this call
MolDx payer-coverage decision on Precise MRD expected H2 2026. Shows if Myriad's oncology test can compete with Natera and Guardant for reimbursed volume.
Myriad's Q2 2026 earnings report due early August 2026. Shows whether guided 2H26 growth reacceleration to double digits actually happens.
Labcorp's cross-sell of former Invitae hereditary tests to physicians. Would show Myriad losing hereditary cancer testing volume to a larger, integrated rival.
Key numbers
  • Q1 2026 revenue $200.4M, up only 2% YoY (2026-Q1)
  • GAAP net loss $34.1M in Q1 2026 (2026-Q1)
  • Market cap $558.7M, stock at $5.71 (2026-07-22)
Named risks
  • Revenue growth stalled to +2% YoY in Q1 2026 after two years of double-digit growth, missed consensus. Severity: high
  • Precise MRD oncology growth depends on pending MolDx payer coverage decisions in H2 2026. Severity: high
  • Three top executive seats (CEO, CFO, CTO) replaced within 14 months, April 2025 to June 2026. Severity: medium
  • Ongoing securities litigation and sector-wide class actions over genetic data use in AI training. Severity: medium
  • Stock trading near 52-week low with high volatility, down ~18% on single earnings day May 2026. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Nateragaining onDescribed as sharp rival outgrowing Myriad in women's health and oncology, 2026-06-18
LabcorpcontestingAcquired bankrupt Invitae's hereditary testing assets for $239M in 2024
Rochegaining onRolled out AI-powered computational pathology March 2025, ahead of Myriad's May 2026 launch
Tempus AI/Ambry GeneticscontestingAmbry hereditary panels now under Tempus AI, competing directly with Myriad's hereditary tests
Questions people ask
Is Myriad Genetics profitable in 2026?
No. Myriad Genetics posted a GAAP net loss of $34.1 million in Q1 2026 on revenue of $200.4 million, up just 2% YoY and below the ~$202.4M consensus estimate, reported May 5, 2026. Adjusted EPS loss was $0.09 versus an expected $0.07 loss.
Has Myriad Genetics had layoffs recently?
No layoffs have been reported for Myriad Genetics in 2025-2026 biotech layoff trackers. Headcount actually grew from about 2,200 in June 2021 to roughly 2,919 by June 2026, a 4.8% year-over-year increase, per Crustdata workforce data as of 2026-06-28.
Could AI replace Myriad Genetics' testing business?
Unlikely to fully replace it. Myriad rents AI as an ingredient, not a substitute: its Prolaris + AI product, launched May 26, 2026, embeds third-party PATHOMIQ AI into pathology scoring, but the company still controls the CLIA lab, payer contracts, and genetic counseling that AI alone cannot replicate.
Who is Myriad Genetics' biggest competitor?
Natera is described as a 'sharp rival' outgrowing Myriad in women's health and oncology as of June 2026. Labcorp also entered hereditary testing by acquiring bankrupt Invitae's assets for $239 million in 2024, and Roche rolled out AI-powered computational pathology in March 2025, ahead of Myriad's own AI launch.
Who owns Myriad Genetics?
Myriad Genetics is an independent public company trading on Nasdaq under ticker MYGN, not a subsidiary. Its market capitalization was approximately $558.7 million as of July 22, 2026, with shares near a 52-week low of $5.71 against a range of $3.53 to $8.59.
What is Myriad Genetics' Precise MRD product and how is it doing?
Precise MRD is Myriad's ctDNA monitoring test, launched in limited release for breast cancer on March 2, 2026, and expanded to colorectal, renal, and breast cancers by June 23, 2026. Its oncology growth depends on pending MolDx Medicare payer-coverage decisions expected in the second half of 2026.
Timeline
  • 2026-07-22Market cap ~$558.7M, stock trading near 52-week low at $5.71
  • 2026-07-21FirstGene Multiple Prenatal Screen fully commercially launched
  • 2026-06-23Precise MRD expanded to colorectal, renal and breast cancer
  • 2026-06Raj Jampa joins as CTO to lead AI and digital transformation
  • 2026-05-26Prolaris + AI launched, combining genomic scoring with PATHOMIQ AI pathology
  • 2026-05-05Q1 2026 results miss consensus; stock falls ~18% same day
  • 2026-04MyChoice test access expanded to prostate cancer patients in Japan
  • 2026-03-02Precise MRD limited commercial launch for breast cancer
  • 2025-08Benjamin Wheeler joins as CFO
  • 2025-04-30Sam Raha becomes President and CEO, replacing Paul Diaz
Head to head
Fulgent Genetics vs Myriad Genetics
Revision history
22 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
NeuralinkKingmed DiagnosticsMeinian Onehealth
More in Medical technology and health companies →
Sources